ArticleVaccines2025
Invasive Meningococcal Disease in the Post-COVID-19 Era in South America.
Article in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Pediatric invasive meningococcal disease in Türkiye during the post-pandemic period: increased reported cases and predominance of serogroup B and severity determined by a clinical form in a multicenter hospital-based cohort.European journal of pediatrics · 2026Article
- Ongoing Outbreak ofOpen forum infectious diseases · 2026Article
- Potential Use of Neisseria meningitidis Serogroup B Vaccines to Prevent Neisseria gonorrhoeae Infection: Epidemiological Considerations.Journal of the International AIDS Society · 2026Review
- Hyperinvasive and quinolone-resistant meningococci cc4821 achieved immune evasion through capsule switching.BMC microbiology · 2026Article
- Nationwide epidemiology of invasive meningococcal disease in Japan, 2017-2025: implications of post-COVID-19 mobility.Tropical medicine and health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundDuring the COVID-19 pandemic, reductions in cases of bacterial diseases transmitted via the respiratory route were reported by the Invasive Respiratory Infection Surveillance Consortium. Here, we evaluate the epidemiology of invasive meningococcal disease (IMD) in Argentina, Brazil, Chile, and Colombia during and after the COVID-19 pandemic.
methodsThe epidemiology of meningococcal disease was reviewed in selected South American countries through 2023 from publicly available national surveillance system databases.
resultsThe incidence of IMD decreased substantially in 2020 in Argentina, Brazil, Chile, and Colombia and was followed by a trend of increased disease. Similarly to observations in several European countries, the post-pandemic rebounds in cases of IMD in the four South American countries included in this analysis were mainly caused by serogroup B, that became one of the predominant serogroups causing IMD in all four countries.
conclusionsEnhanced surveillance of IMD, including genomic characterization of strains, is needed to inform public health policymakers and guide future vaccination strategies in the region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.